Tag Archives: Xtandi

Xtandi, Bayh-Dole, and how Pfizer might stop worrying and love the march in

Posted on March 23, 2023 by Gerald Barnett

The American Prospect has an interesting piece (“A Big Miss on Drug Prices”) on the NIH yet again defying the Bayh-Dole Act and refusing to launch an investigation into whether UCLA and Pfizer have met Bayh-Dole’s standard (35 USC 201(f)) … Continue reading →

Posted in Bayh-Dole | Tagged , , , , | Comments Off on Xtandi, Bayh-Dole, and how Pfizer might stop worrying and love the march in

March-in rights, Xtandi, and Bayh-Dole’s patent rights clause

Posted on March 3, 2023 by Gerald Barnett

Senator Bernie Sanders just tweeted about Xtandi, asking patients taking Xtandi to share their stories. The prostate cancer drug Xtandi was invented by taxpayer-funded scientists at UCLA, but now costs Americans nearly $190,000 — or up to six times the … Continue reading →

Posted in Bayh-Dole, high priced drugs | Tagged , , , , | Comments Off on March-in rights, Xtandi, and Bayh-Dole’s patent rights clause

An Open Letter to Senator Warren Regarding Xtandi

Posted on January 16, 2023 by Gerald Barnett

Dear Senator Warren: You have called repeatedly for the federal government to use regulatory tools available to it to address the high prices charged for drugs. Your attention to this matter is much appreciated! I write with specific reference to … Continue reading →

Posted in Bayh-Dole, Policy | Tagged , , , | Comments Off on An Open Letter to Senator Warren Regarding Xtandi

The failed Bayh-Dole bargain, 4

Posted on August 14, 2022 by Gerald Barnett

Finally, we reach Xtandi. The authors provide the pricing of $156,000 per year, but don’t point out that generic manufacturers have offered to produce Xtandi for $3 per pill–or about $4,300 per year. There’s a claim that Astellas has spent $1.4 … Continue reading →

Posted in Bayh-Dole | Tagged , , , | Comments Off on The failed Bayh-Dole bargain, 4

Undermining Bayh-Dole by relying on it? 5

Posted on March 14, 2022 by Gerald Barnett

Now for Reimers’s new op/ed, making more arguments against march-in, but now directed at Xtandi, a prostate cancer drug based on a series of compounds developed at UCLA with federal funding. According to Knowledge Ecology International, Xtandi is offered for … Continue reading →

Posted in Bayh-Dole | Tagged , , , | Comments Off on Undermining Bayh-Dole by relying on it? 5

Xtandi demonstrates how Bayh-Dole is a do WTF you want law, 3

Posted on March 16, 2018 by Gerald Barnett

The first part of this article is here. The exclusive license that UCLA granted to Medivation meets the requirements for an assignment of the subject invention. The license grants substantially all rights in the subject invention (to all compounds for … Continue reading →

Posted in Bayh-Dole | Tagged , , , , , , | Comments Off on Xtandi demonstrates how Bayh-Dole is a do WTF you want law, 3

Xtandi demonstrates how Bayh-Dole is a do WTF you want law, 2

Posted on March 15, 2018 by Gerald Barnett

The first part of this article is here. To explore these issues, let’s take a look at Xtandi, a prostate cancer drug that has received press recently in the debate over high drug prices. Xtandi sells in the U.S. for … Continue reading →

Posted in Bayh-Dole | Tagged , , , , , , , | Comments Off on Xtandi demonstrates how Bayh-Dole is a do WTF you want law, 2

Xtandi demonstrates how Bayh-Dole is a do WTF you want law, 1

Posted on March 14, 2018 by Gerald Barnett

There is a big divide regarding what Bayh-Dole was supposed to accomplish with regard to the use of patents on publicly funded research. On one side is the view that publicly supported research should be freely or otherwise reasonably available … Continue reading →

Posted in Bayh-Dole | Tagged , , , , , , | Comments Off on Xtandi demonstrates how Bayh-Dole is a do WTF you want law, 1

Use the government license in Bayh-Dole

Posted on April 18, 2017 by Gerald Barnett

According to news reports (here’s where I first read about it–follow the link there to the article in the Baltimore Sun), the state of Maryland is attempting to deal with high drug prices through legislation that gives the state the right … Continue reading →

Posted in Bayh-Dole, Freedom, Policy | Tagged , , , , | Comments Off on Use the government license in Bayh-Dole

Use Bayh-Dole 35 USC 202(a)(ii) to deal with (future) drug prices

Posted on October 29, 2016 by Gerald Barnett

The Washington Monthly has a new article out by Alicia Mundy on high drug prices and Bayh-Dole. Mundy reports on efforts to use march-in procedures under Bayh-Dole to force lower the price of drugs that were developed with federal support. There’s substance … Continue reading →

Posted in Bayh-Dole, Policy | Tagged , , | Comments Off on Use Bayh-Dole 35 USC 202(a)(ii) to deal with (future) drug prices